CeMM Adjunct Principal Investigator

Thomas Reiberger
Rare Liver Diseases & Hepatic Microcirculation

Prof. Dr. Thomas Reiberger
Medical University of Vienna
Department of Internal Medicine III
Div. of Gastroenterology & Hepatology
Vienna Hepatic Experimental Hemodynamic Lab
Waehringer Guertel 18-20, 1090 Vienna

Website

Thomas Reiberger conducted seminal studies for optimizing the role of non-selective betablocker therapy in patients with cirrhosis and portal Hypertension (Reiberger, Gut, 2013; Mandorfer, Gastroenterology 2015; Reiberger, Journal of Hepatology, 2017). His HEPEX research team is focused on exploring novel treatment options for liver fibrosis and portal hypertension, such as anti-angiogenic drugs (Reiberger, Journal of Hepatology 2009), FXR agonsits (Schwabl, Journal of Hepatology, 2017) and soluble guanylate cyclase stimulators (Schwabl, Scientific Reports 2018). Thomas Reiberger is also the clinical director of the cirrhosis outpatient clinic and the Vienna Hepatic Hemodynamic Laboratory at the Division of Gastroenterology & Hepatology.

Main Research Interests:
Liver fibrogensis and inflammation
Portal hypertension
Rare liver diseases causing non-cirrhotic portal hypertension

Biosketch

Thomas Reiberger, born in 1982, joined the LBI-RUD and CeMM in November 2018 as an Adjunct PI. After obtaining his MD at the Medical University of Vienna, he did a first postdoc at the Department of Pathophysiology at the Medical University of Vienna focusing on ex-situ liver perfusion and liver cell biology. During his residency for Internal Medicine, Thomas pursued a career as a physician-scientist by performing translational clinical studies on portal hypertension and fibrosis in patients with viral hepatitis. In addition to his clinical activity, he established the Vienna Hepatic Experimental (HEPEX) Laboratory at the Medical University of Vienna. In 2011, he received his Venia Docendi and in 2012 he obtained his board certification for Internal Medicine. After another postdoctoral fellowship in the United States from 2012 to 2015, Thomas Reiberger joined the Faculty at the Division of Gastroenterology and Hepatology at the Medical University of Vienna. Thomas conducted seminal studies for optimizing the role of non-selective betablocker therapy in cirrhotic patients with portal hypertension. The main mission of his HEPEX research team is the exploration of novel treatment options for liver fibrosis and portal hypertension, such as anti-angiogenic drugs, FXR agonists and modulators of the soluble guanylyl cyclase. Thomas Reiberger is also the director of the Cirrhosis Outpatient Clinic and the Vienna Hepatic Hemodynamic Laboratory at the Medical University of Vienna. In his role as the coordinator of the Rare Liver Disease (RALID) Center of the European Reference Network (ERN) at the Medical University of Vienna, he complements the mission of the LBI-RUD with translational research supported by the RALID center.

Selected Papers

Reiberger T, et al. Beta adrenergic blockade and decompensated cirrhosis. J Hepatol. 2017 Apr;66(4):849-859. (abstract)

Reiberger T, et al. An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. Nature Protocols. 2015; 10(8):1264-74. (abstract)

Reiberger T, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013 Nov;62(11):1634-41. (abstract)

Reiberger T, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013 May;58(5):911-21. (abstract)

Reiberger T, et al. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. J Hepatol. 2009 Nov;51(5):865-73. (abstract)